These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 24582381)

  • 1. The role of evidence and the expert in contemporary processes of governance: the case of opioid substitution treatment policy in England.
    Duke K; Thom B
    Int J Drug Policy; 2014 Sep; 25(5):964-71. PubMed ID: 24582381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substitution treatment in the era of "recovery": An analysis of stakeholder roles and policy windows in Britain.
    Duke K; Herring R; Thickett A; Thom B
    Subst Use Misuse; 2013 Aug; 48(11):966-76. PubMed ID: 23952509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stakeholders' role in contemporary "substitute drug" prescribing policies in Italy.
    Beccaria F; Rolando S
    Subst Use Misuse; 2013 Aug; 48(11):943-53. PubMed ID: 23952507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shifts in opioid substitution treatment policy in Denmark from 2000-2011.
    Frank VA; Bjerge B; Houborg E
    Subst Use Misuse; 2013 Aug; 48(11):997-1009. PubMed ID: 23952511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stakeholders in opioid substitution treatment policy: similarities and differences in six European countries.
    Thom B; Duke K; Frank VA; Bjerge B
    Subst Use Misuse; 2013 Aug; 48(11):933-42. PubMed ID: 23952506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 'Naloxone works': The politics of knowledge in 'evidence-based' drug policy.
    Lancaster K; Treloar C; Ritter A
    Health (London); 2017 May; 21(3):278-294. PubMed ID: 28135864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Governance versus government: drug consumption rooms in Australia and the UK.
    Zampini GF
    Int J Drug Policy; 2014 Sep; 25(5):978-84. PubMed ID: 24746642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The science and practice of medication-assisted treatments for opioid dependence.
    Pecoraro A; Ma M; Woody GE
    Subst Use Misuse; 2012; 47(8-9):1026-40. PubMed ID: 22676570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European micronutrient recommendations aligned: a general framework developed by EURRECA.
    Dhonukshe-Rutten RA; Timotijevic L; Cavelaars AE; Raats MM; de Wit LS; Doets EL; Tabacchi G; Roman B; Ngo-de la Cruz J; Gurinovic M; de Groot LC; van 't Veer P
    Eur J Clin Nutr; 2010 Jun; 64 Suppl 2():S2-10. PubMed ID: 20517317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug consumption rooms and the role of politics and governance in policy processes.
    Houborg E; Frank VA
    Int J Drug Policy; 2014 Sep; 25(5):972-7. PubMed ID: 24572642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Commentary on "Substitution treatment in the era of 'recovery': an analysis of stakeholder roles and policy windows in Britain".
    Neale J
    Subst Use Misuse; 2013 Aug; 48(11):1059-60. PubMed ID: 23952515
    [No Abstract]   [Full Text] [Related]  

  • 12. Power relations and contrasting conceptions of evidence in patient-involvement processes used to inform health funding decisions in Australia.
    Lopes E; Carter D; Street J
    Soc Sci Med; 2015 Jun; 135():84-91. PubMed ID: 25950114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behind the scenes: the justifications for opioid maintenance treatment in Finland.
    Perälä R; Hellman M; Leppo A
    Subst Use Misuse; 2013 Aug; 48(11):954-65. PubMed ID: 23952508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Walking through mud; history of the Polish methadone maintenance treatment from its stakeholders' perspective.
    Moskalewicz J; Welbel M
    Subst Use Misuse; 2013 Aug; 48(11):977-96. PubMed ID: 23952510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Social construction and the evidence-based drug policy endeavour.
    Lancaster K
    Int J Drug Policy; 2014 Sep; 25(5):948-51. PubMed ID: 24491356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Making drug policy together: reflections on evidence, engagement and participation.
    Roberts M
    Int J Drug Policy; 2014 Sep; 25(5):952-6. PubMed ID: 24882708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is good governance in the context of drug policy?
    Singleton N; Rubin J
    Int J Drug Policy; 2014 Sep; 25(5):935-41. PubMed ID: 24768218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intelligent policy making? Key actors' perspectives on the development and implementation of an early years' initiative in Scotland's public health arena.
    Deas L; Mattu L; Gnich W
    Soc Sci Med; 2013 Nov; 96():1-8. PubMed ID: 24034945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deviance or innovation? Recent changes of drug substitution treatment policy in Austria.
    Eisenbach-Stangl I
    Subst Use Misuse; 2013 Aug; 48(11):1010-21. PubMed ID: 23952512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug Policy Governance in the UK: lessons from changes to and debates concerning the classification of cannabis under the 1971 Misuse of Drugs Act.
    Monaghan M
    Int J Drug Policy; 2014 Sep; 25(5):1025-30. PubMed ID: 24635973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.